Background Only clinically validated HPV assays can be accepted in cervical cancer
screening. Objectives To update the list of high-risk HPV assays that fulfil the 2009 …

Background Cytology-based screening has been a cornerstone of cervical cancer
prevention for decades. Following extensive evidence demonstrating higher sensitivity and …

The COVID-19 pandemic has a major impact on a wide range of health outcomes.
Disruptions of elective health services related to cervical screening, management of …

This paper briefly reviews the role of hypermethylation of host cell genes in cervical
carcinogenesis and discusses potential clinical applications of methylation analysis in the …

Abstract HPV self-sampling (HPV-SS) can increase cervical cancer screening participation
by addressing barriers in high-and low-and middle-income settings. Successful …

In 2020, approximately 604 127 patients were newly diagnosed with cervical cancer and
341 831 died of the disease worldwide. Unfortunately, 85–90% of new cases and deaths …

Viruses are the most abundant and genetically diverse entities on the planet, infect all life
forms and have evolved with their hosts. To date, 263 viral species have been identified that …

Background Stimulator of interferon genes (STING) is an innate immune sensor of
cytoplasmic double-stranded DNA originating from microorganisms and host cells. The …

Background: Some countries have implemented stand-alone human papillomavirus (HPV)
testing while others consider cotesting for cervical cancer screening. We compared both …

Objective To compare the costs and effects of three sampling strategies for human
papillomavirus (HPV) primary screening. Design Cost-consequence analysis from a health …